Drug Search Results
More Filters [+]

Derazantinib

Alternative Names: derazantinib, arq-087, arq087, arq 087
Latest Update: 2024-07-24
Latest Update Note: Clinical Trial Update

Product Description

Derazantinib (formerly ARQ 087) is an investigational orally administered small-molecule panFGFR kinase inhibitor with strong activity against FGFR1, 2, and 3.5 FGFR kinases are key drivers of cell proliferation, differentiation and migration.

Mechanisms of Action: FGFR2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Basilea Pharmaceutica
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Derazantinib

Countries in Clinic: Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Ireland, Italy, Korea, Poland, Spain, Switzerland, United Kingdom, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 2: Cholangiocarcinoma|Hepatocellular Carcinoma|Transitional Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2020-004938-38

P2

Active, not recruiting

Cholangiocarcinoma

2025-12-08

2019-000359-15

P2

Active, not recruiting

Transitional Cell Carcinoma

2022-11-08

FIDES-01

P2

Completed

Cholangiocarcinoma|Hepatocellular Carcinoma

2022-10-25

FIDES-02

P2

Completed

Transitional Cell Carcinoma

2022-10-04

Recent News Events